Their main aim is commercialization of molecular diagnostics for the detection and management of cancer.
Their target is "detection, diagnosis and management of cancer." DiangoCure offers molecular diagnostic tests that show you particularities in genes connected with cancer. This company was established in 1994, DiagnoCure commercialized its first diagnostic test, ImmunoCyt™ / uCyt+™ for bladder cancer, in Europe in 1998.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
4535 Wilfrid-Hamel Blvd, Suite 250